NASDAQ · BCAX
Bicara Therapeutics Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for BCAX: Nov 9, 2026
Bicara Therapeutics Inc. Common Stock is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.84. The reported EPS for the same quarter last year was $-0.67.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.84 | $-0.81 | $-0.87 | 6 |
| Dec 2026 | $-0.89 | $-0.85 | $-0.96 | 5 |
| Mar 2027 | $-0.90 | $-0.87 | $-0.94 | 3 |
| Jun 2027 | $-0.93 | $-0.89 | $-0.99 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · The Motley Fool · MarketBeat · Fintel- RTTNews · Oct 1, 5:00 AM EDTPliant Therapeutics Names David Raben As CMO To Lead PLN-101095 Development(RTTNews) – Pliant Therapeutics (PLRX), a clinical-stage biotechnology company focused on developing integrin-based therapeutics, announced the appointment of David Raben, M.D., as Chief Medical Officer.
- The Motley Fool · Aug 18, 11:13 AM EDTBicara Therapeutics (BCAX) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Aug 12, 2:56 AM EDTBicara Therapeutics Q2 Net Loss Expands; Phase 3 FORTIFI-HN01 Study Enrollment On Track(RTTNews) – Bicara Therapeutics Inc. (BCAX), a clinical-stage biopharmaceutical company, announced financial results for the second quarter reflecting a wider net loss. In addition, the company announced a few management changes and provided an update on its lead investigational
- MarketBeat · Aug 11, 10:04 AM EDTBicara Therapeutics Q2 Earnings Call HighlightsBicara Therapeutics (NASDAQ:BCAX) used its second-quarter 2026 earnings call to outline leadership changes, progress in its pivotal head and neck cancer program and plans to expand development of ficerafusp alfa, or FICERA, while reaffirming its cash runway into the first half of
- The Motley Fool · Jun 13, 1:21 AM EDTWhat Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?CEO Claire Mazumdar sold 15,000 shares for a transaction value of approximately ~$301,000, based on a weighted average price of around $20.04 per share on May 18, 2026.
- The Motley Fool · Jun 1, 12:13 PM EDTBicara (BCAX) Q4 2025 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · May 22, 11:09 AM EDTBicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck CancerBicara Therapeutics (NASDAQ:BCAX) said new data to be presented at the 2026 American Society of Clinical Oncology annual meeting support the clinical profile of ficerafusp alfa, also referred to by the company as Ficara, in first-line recurrent or metastatic HPV-negative head and
- The Motley Fool · May 15, 7:02 PM EDTBicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio BetOmega Fund increased its BCAX stake by 187,500 shares in the first quarter; the estimated trade size was $3.23 million (based on average quarterly prices).
- MarketBeat · May 14, 5:09 PM EDTBicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal DataBicara Therapeutics (NASDAQ:BCAX) said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development strategy and competitive positioning at the Bank of America Healthcare Conference
- Fintel · May 11, 8:04 PM EDTGuggenheim Initiates Coverage of Bicara Therapeutics (BCAX) with Buy RecommendationFintel reports that on May 11, 2026, Guggenheim initiated coverage of Bicara Therapeutics (NasdaqGM:BCAX) with a Buy recommendation. Analyst Price Forecast Suggests 35.91% Upside
- The Motley Fool · May 11, 1:40 PM EDTBicara (BCAX) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · May 11, 10:31 AM EDTBicara Records $56 Mln Loss In Q1; Provides Updates On Ficerafusp Alfa Trials(RTTNews) – Bicara Therapeutics Inc. (BCAX), a clinical-stage biopharmaceutical company, on Monday released the first quarter financial results and provided business updates for its lead candidate ficerafusp alfa.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Bicara Therapeutics Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.